根据协议条款，艾伯维将在交易完成时支付2亿美元现金用于收购Nimble，同时提供一定的中期资金支持。此外，Nimble的股东在达成特定开发里程碑后，还将有机会获得额外的潜在付款。AbbVie (ABBV.US) announced the final agreement with Nimble Therapeutics.
According to Zhito Finance APP, AbbVie (ABBV.US) announced that it has reached a final agreement to acquire Nimble, obtaining its core Assets, including the key project - oral peptide IL-23 receptor (IL-23R) inhibitor, as well as an innovative pipeline of oral peptide candidates covering various autoimmune diseases. In addition, AbbVie will also gain Nimble's peptide synthesis, screening, and optimization platform, which uses proprietary technology to accelerate the discovery and optimization of peptide candidates targeting multiple targets.
Nimble is a Biotechnology company focused on developing oral peptide therapies, advancing its internal pipeline research and multiple collaborative projects through its transformative peptide drug discovery and development platform. This platform integrates large-scale parallel solid-phase synthesis, diverse chemical and structural libraries, complex screening methods, and advanced machine learning and computational techniques.
Under the terms of the agreement, AbbVie will pay $0.2 billion Cash to acquire Nimble upon completion of the Trade, while providing certain mid-term funding support. In addition, Nimble's Shareholders will have the opportunity to receive additional potential payments upon achieving specific development milestones.